BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/15/2023 6:05:28 AM | Browse: 242 | Download: 859
 |
Received |
|
2023-01-26 12:20 |
|
Peer-Review Started |
|
2023-01-26 12:24 |
|
First Decision by Editorial Office Director |
|
2023-04-11 16:52 |
|
Return for Revision |
|
2023-04-11 16:52 |
|
Revised |
|
2023-04-14 08:12 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-05-04 03:13 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-05-05 15:34 |
|
Articles in Press |
|
2023-05-05 15:34 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-06-08 08:43 |
|
Publish the Manuscript Online |
|
2023-06-15 06:05 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana, Tawithep Leowattana and Pathompthep Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, BMed, MD, MSc, PhD, Full Professor, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi Road, Rachatawee 10400, Bangkok, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
Biliary tract cancers; Gemcitabine and cisplatin combination; Fibroblast growth factor receptor 2 inhibitors; Isocitrate dehydrogenase 1 inhibitors; Neurotrophic tyrosine receptor kinase gene fusion inhibitors; Immune checkpoint inhibitors; Microsatellite instability high; Infrigatinib; Pemigatinib |
| Core Tip |
There have been several developments in the field of advanced biliary tract cancer (BTC) therapy in recent years. First, the care of these hepatobiliary malignancies has improved as a result of better knowledge of the molecular basis of BTC. The Food and Drug Administration's approval of pemigatinib, infigratinib, and ivosidenib for fibroblast growth factor receptor 2-rearranged and isocitrate dehydrogenase 1-mutant cholangiocarcinoma illustrates the paradigm shift that the arrival of targeted agents has really brought about. Second, patients receiving modified fluorouracil, oxaliplatin, and liposomal irinotecan with fluorouracil-leucovorin, respectively, as second-line treatments after progressing to first-line cisplatin-gemcitabine, showed an overall survival advantage in the newly released Advanced Biliary Tract Cancer-06 and NIFTY studies. |
| Publish Date |
2023-06-15 06:05 |
| Citation |
Leowattana W, Leowattana T, Leowattana P. Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer. World J Gastrointest Oncol 2023; 15(6): 959-972 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i6/959.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i6.959 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
